We are live on
!
Find out more
PC
Polar Capital Portfolio holdings
AUM
$13.5B
1-Year Est. Return
55.9%
This Fund
S&P 500
This Quarter
Est. Return
+4.91%
1 Year Est. Return
+55.9%
3 Year Est. Return
+127.44%
5 Year Est. Return
+269.08%
10 Year Est. Return
–
AUM
$5.3B
AUM Growth
-$16.8M
(-0.32%)
Cap. Flow
-$266M
Cap. Flow
% of AUM
-5.01%
Top 10 Holdings %
Top 10 Hldgs %
22.18%
Holding
297
New
35
Increased
74
Reduced
86
Closed
35
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pfizer
PFE
|
+$60.5M |
| 2 |
S&P Global
SPGI
|
+$52.3M |
| 3 |
Bristol-Myers Squibb
BMY
|
+$41.3M |
| 4 |
AGN
Allergan plc
AGN
|
+$38.2M |
| 5 |
LVNTA
Liberty Interactive Corporation Series A Liberty Ventures
LVNTA
|
+$37.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Johnson & Johnson
JNJ
|
+$98.3M |
| 2 |
Eli Lilly
LLY
|
+$54.1M |
| 3 |
Apple
AAPL
|
+$51.2M |
| 4 |
Fidelity National Information Services
FIS
|
+$42.9M |
| 5 |
Stryker
SYK
|
+$40.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 25.18% |
| 2 | Financials | 21.66% |
| 3 | Technology | 21.39% |
| 4 | Communication Services | 9.45% |
| 5 | Consumer Discretionary | 5.7% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ISEE
201
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $2.2M | 0.04% |
43,076
+23,756
| +123% | +$1.18M |
|
|
HR
202
DELISTED
Healthcare Realty Trust Incorporated
HR
| $2.1M | 0.04% |
60,000
| – | – |
|
|
DHC
203
Diversified Healthcare Trust
DHC
$2.26B
| $2.08M | 0.04% |
100,000
| – | – |
|
|
RDUS
204
DELISTED
Radius Health, Inc.
RDUS
| $1.93M | 0.04% |
52,581
+13,892
| +36% | +$491K |
|
205
Tesla
TSLA
$1.24T
| $1.93M | 0.04% |
+136,200
| New | +$2.06M |
|
206
New Mountain Finance
NMFC
$646M
| $1.9M | 0.04% |
147,500
| – | – |
|
207
National Health Investors
NHI
$3.9B
| $1.88M | 0.04% |
25,000
| – | – |
|
|
ALDR
208
DELISTED
Alder Biopharmaceuticals
ALDR
| $1.87M | 0.04% |
+75,000
| New | +$2.03M |
|
209
Telus
TU
$16B
| $1.84M | 0.03% |
99,000
| – | – |
|
|
NVDQ
210
DELISTED
Novadaq Technologies Inc.
NVDQ
| $1.72M | 0.03% |
175,000
+45,000
| +35% | +$481K |
|
211
East-West Bancorp
EWBC
$17.9B
| $1.71M | 0.03% |
50,000
| – | – |
|
212
Omega Healthcare
OHI
$15.4B
| $1.7M | 0.03% |
50,000
| – | – |
|
|
CSLT
213
DELISTED
CASTLIGHT HEALTH, INC.
CSLT
| $1.65M | 0.03% |
419,704
+158,246
| +61% | +$621K |
|
214
Pacira BioSciences
PCRX
$1.02B
| $1.63M | 0.03% |
48,196
+22,162
| +85% | +$1.09M |
|
215
Healthcare Services Group
HCSG
$1.56B
| $1.59M | 0.03% |
38,372
| – | – |
|
216
NXP Semiconductors
NXPI
$68B
| $1.55M | 0.03% |
19,780
-49,800
| -72% | -$4.27M |
|
217
Sabra Healthcare REIT
SBRA
$5.64B
| $1.55M | 0.03% |
75,000
| – | – |
|
|
SHPG
218
DELISTED
Shire pic
SHPG
| $1.42M | 0.03% |
+7,722
| New | +$1.39M |
|
|
NSTG
219
DELISTED
NanoString Technologies, Inc.
NSTG
| $1.26M | 0.02% |
100,000
+35,000
| +54% | +$508K |
|
220
DexCom
DXCM
$27.6B
| $1.2M | 0.02% |
60,652
-835,348
| -93% | -$14.2M |
|
|
MTLS
221
Materialise
MTLS
$379M
| $1.19M | 0.02% |
166,991
+26,212
| +19% | +$187K |
|
|
ALXN
222
DELISTED
Alexion Pharmaceuticals
ALXN
| $1.11M | 0.02% |
9,520
-15,799
| -62% | -$2.24M |
|
223
Altria Group
MO
$122B
| $1.07M | 0.02% |
15,500
| – | – |
|
224
HDFC Bank
HDB
$119B
| $1.05M | 0.02% |
63,068
-8,540
| -12% | -$136K |
|
225
Comscore
SCOR
$110M
| $1.04M | 0.02% |
2,169
-2,881
| -57% | -$1.72M |
|
Similar funds
ECM
FAAS
WAM
FS
NIMC
TI
VIM
PS
Polar Capital's Q2 2016 Portfolio in Review
As of Q2 2016, Polar Capital held 297 positions worth $5.3B, down 0.32% from $5.32B the previous quarter. Its ten largest holdings account for 22% of the portfolio.
Polar Capital withdrew a net $266M in Q2 2016, closing 35 positions and reducing 86 holdings. Its most notable exit was Stryker, an estimated $40.2M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 25% of assets, up from 23% a quarter earlier, followed by Financials and Technology.
Against the trend, Polar Capital opened a new position in S&P Global worth $52.2M.
- Polar Capital's largest Q2 2016 buy was S&P Global: 487,049 shares worth $52.2M.
- Polar Capital added most to Pfizer in Q2 2016, an estimated $60.5M increase.
- Polar Capital's biggest Q2 2016 reduction was Johnson & Johnson, cutting an estimated $98.3M.
- Polar Capital fully exited Stryker in Q2 2016, selling an estimated $40.2M.
- Polar Capital's ten largest holdings make up 22% of its $5.3B portfolio in Q2 2016.
- Polar Capital opened 35 new positions and closed 35 in Q2 2016.
- Polar Capital's portfolio value fell 0.32% quarter-over-quarter to $5.3B.
Based on Polar Capital's 13F filing for Q2 2016, filed 15 Aug 2016.